Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EPO patent dispute

Executive Summary

Genetics Institute files motion for summary judgment in Massachusetts federal court in connection with a patent infringement suit against Amgen covering erythropoietin. Amgen filed a product license application for recombinant EPO at the end of 1987. Genetics Institute has also filed suit in San Francisco federal court against Amgen's licensee Ortho. In a separate action, the International Trade Commission voted to initiate an investigation of Amgen's complaint that Genetics Institute's licensee Chugai violated federal law by importing EPO into the U.S. The Section 337 investigation is expected to take from 12-18 months, ITC said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS013138

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel